Also Known As
Presenilin 1 Gene
Formal Name
PS1 or PSEN1 Genetic Mutation Analysis
This article was last reviewed on
This article waslast modified on December 26, 2018.
At a Glance
Why Get Tested?

To screen for a rare mutation in the PSEN1 gene known to be associated with early onset familial Alzheimer disease (EOFAD, also called Alzheimer disease type 3 or AD3)

When To Get Tested?

When you are an adult who has symptoms of dementia and a strong family history of Alzheimer disease that begins before age 60-65 or if you are an asymptomatic adult with a family member who has early onset Alzheimer disease and an identified PSEN1 genetic mutation

Sample Required?

A blood sample drawn from a vein in your arm

Test Preparation Needed?


You may be able to find your test results on your laboratory's website or patient portal. However, you are currently at Lab Tests Online. You may have been directed here by your lab's website in order to provide you with background information about the test(s) you had performed. You will need to return to your lab's website or portal, or contact your healthcare practitioner in order to obtain your test results.

Lab Tests Online is an award-winning patient education website offering information on laboratory tests. The content on the site, which has been reviewed by laboratory scientists and other medical professionals, provides general explanations of what results might mean for each test listed on the site, such as what a high or low value might suggest to your healthcare practitioner about your health or medical condition.

The reference ranges for your tests can be found on your laboratory report. They are typically found to the right of your results.

If you do not have your lab report, consult your healthcare provider or the laboratory that performed the test(s) to obtain the reference range.

Laboratory test results are not meaningful by themselves. Their meaning comes from comparison to reference ranges. Reference ranges are the values expected for a healthy person. They are sometimes called "normal" values. By comparing your test results with reference values, you and your healthcare provider can see if any of your test results fall outside the range of expected values. Values that are outside expected ranges can provide clues to help identify possible conditions or diseases.

While accuracy of laboratory testing has significantly evolved over the past few decades, some lab-to-lab variability can occur due to differences in testing equipment, chemical reagents, and techniques. This is a reason why so few reference ranges are provided on this site. It is important to know that you must use the range supplied by the laboratory that performed your test to evaluate whether your results are "within normal limits."

For more information, please read the article Reference Ranges and What They Mean.

What is being tested?

This test looks for mutations in the PSEN1 gene sequence that have been associated with early onset familial Alzheimer disease (EOFAD, also called Alzheimer disease type 3 or AD3).

Although most Alzheimer disease (AD) cases start after the age of 65, about 5-10% of cases begin in people younger than 65 years of age. Much of this early onset AD is familial – it runs in family lines and is caused by a genetic mutation. So far, there have been three rare gene mutations that have been identified as being associated with AD3: PSEN1, PSEN2, and amyloid precursor protein (APP).

PSEN1 is the most common of these gene mutations and is thought to cause about 30% to 70% of the cases of AD3. Since PSEN1 is a dominant gene (autosomal dominant), it only takes one mutated copy, inherited from either the mother or father, to lead to the development of AD3.

Why PSEN1 mutations are associated with AD3 is not completely understood. It is thought that the normal role of the PSEN1 gene is to make the presenilin 1, a protein used in the development of the brain and spinal cord. Presenilin 1 also works with other enzymes to cut certain proteins into smaller pieces (amyloid beta peptide). A mutation of PSEN1 produces an abnormal presenilin 1 protein that no longer functions properly, resulting in a breakdown of this process. This breakdown lends itself to increased production of a longer, stickier configuration of the amyloid beta protein, which is toxic to the nervous system and eventually forms the characteristic amyloid plaques seen with AD.

So far, more than 150 mutations of the PSEN1 gene have been identified in a limited number of different family lines worldwide. The large number of mutations suggests that there may be additional mutations not yet known; thus, the PSEN1 test will not identify every person who has a PSEN1 mutation.

The analysis is made easier if a specific PSEN1 mutation has already been identified in a person's family line. The PSEN1 genetic mutation analysis is a relatively new test and is offered by a limited number of laboratories.

How is the sample collected for testing?

A blood sample is obtained by inserting a needle into a vein in the arm.

Is any test preparation needed to ensure the quality of the sample?

No test preparation is needed.

Accordion Title
Common Questions
  • How is it used?

    PSEN1 genetic mutation analysis is used to screen asymptomatic or symptomatic adults who have a strong family history of early onset Alzheimer disease (EOFAD, also called Alzheimer disease type 3 or AD3), especially when a specific PSEN1 mutation has been identified in other family members. It may be used to aid in the differential diagnosis of EOFAD versus other forms of early onset dementia but usually only in those with a family history of AD3. Appropriate genetic counseling may be pursued to assess the risk of either parent having and passing on a PSEN1 mutation. However, PSEN1 testing is rarely ordered prenatally because an amniocentesis is required and because it is not common practice to test prenatally for adult-onset diseases.

    The PSEN1 test is not useful as a screen for the general population or for those who have late onset AD.

  • When is it ordered?

    This test may be ordered when a person develops symptoms associated with Alzheimer disease before 65 years of age. PSEN1 mutation analysis may also be ordered when an asymptomatic adult has a strong family history of early onset Alzheimer disease, especially when there are multiple family members over several generations who have had or were thought to have had AD3.

    Very rarely, PSEN1 testing may be ordered prenatally when there are documented affected family members and a specific PSEN1 gene mutation has been identified in a family member. It is not common practice to test prenatally or to test children for adult-onset diseases.

  • What does the test result mean?

    If a person has one of the PSEN1 mutations, it is highly likely that the person will eventually develop AD3, usually at a similar age to other affected family members. The penetrance of the gene (i.e., the symptoms, the severity, and the rate of progression) can vary from individual to individual. Since it is a dominant gene, each child will have a 50% chance of having the PSEN1 mutation passed on to them.

    If the PSEN1 genetic mutation analysis is negative, it is still possible that the person has AD3 because the mutation is not able to be identified by the existing testing method and may be due to a different mutation of the PSEN1 gene or a mutation of another gene yet to be identified.

  • Is there anything else I should know?

    The PSEN1 genetic mutation is almost exclusively family-related and is not associated with late onset AD. A few cases of PSEN1 genetic mutation will show up without a strong family history because of "alternate" paternity, new mutations, or because a parent died before symptoms developed so this element of the family history was unknown.

    The PSEN1 test is a relatively new, comparatively expensive test that has limited use and is still rarely ordered. It is performed in only a few laboratories, so if a health practitioner recommends the test, the blood sample will need to be sent to a reference laboratory and results may take awhile to return. As with many new testing modalities, the analysis may be costly and is often not covered under most insurance plans.

  • My father has been diagnosed with early onset Alzheimer disease (AD3). Can my doctor tell if my father has a genetic mutation without a blood test?

    No, the symptoms for AD3, sporadic early onset AD, and late onset AD are the same except for the age of onset. You cannot tell whether someone has a genetic mutation just by looking at their perceived abnormal daily living activities. If there is a strong family history of early onset AD, especially if another family member has been diagnosed with a genetic mutation, your doctor may suspect a genetic problem that may be confirmed by a blood test.

  • Are there any other genetic tests that will diagnose AD?

    The other genes that have mutations associated with AD3 are PSEN2 and APP (amyloid precursor protein). Testing is available, but it should be noted that these gene mutations are very rare and have only been identified in a very small number of specific family lines.

View Sources

Sources Used in Current Review

Grandy, J. (2011 June 16). What's new in Alzheimer disease? Biomarkers and gene mutations as aids for detecting AD early. JAAPA [On-line information]. Available online at through Accessed April 2013.

Bird, T. (Revised 2012 October 18). Early-Onset Familial Alzheimer Disease. NCBI GeneReview [On-line information]. Available online at through Accessed March 2014.

Mayo Clinic Staff (2011 March 31) Early-onset Alzheimer's: When symptoms begin before age 65. Mayo Clinic [On-line information]. Available online at through Accessed March 2014.

Bird, T. (Revised 2014 January 30). Alzheimer Disease Overview. NCBI GeneReview [On-line information]. Available online at through Accessed March 2014.

Mayo Clinic Staff (2013 February 9). Alzheimer's genes: Are you at risk? Mayo Clinic through Accessed March 2014.

Anderson, H. (Updated 2014 March 3). Alzheimer Disease. Medscape Reference [On-line information]. Available online at through Accessed March 2014.

Stetka, B. (2013 April 1). Alzheimer Biomarkers in Clinical Practice. Medscape Today News [On-line information]. Available online at through Accessed March 2014.

Sources Used in Previous Reviews

Thomas, Clayton L., Editor (1997). Taber's Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].

Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby's Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.

Sloane, P. (1998, November 1). Advances in the Treatment of Alzheimer's Disease. American Family Physician by the American Academy of Family Physicians [On-line journal]. Available online at through

Eastman, P. (2002 March). Keeping Alzheimer's at Bay, Early Diagnosis Keeps Patients Functioning Longer. AARP Bulletin Online [On-line serial]. Available online at through

McConnell, S. et. al. Unraveling the Mysteries of Alzheimer's Disease: Exciting New Developments in Research. From panel sponsored by the Alzheimer's Association [On-line information]. Available online at through

Galasko, D., et. al. (1998). High Cerebrospinal Fluid Tau and Low Amyloid b42 Levels in the Clinical Diagnosis of Alzheimer Disease and Relation to Apolipoprotein E Genotype. Arch Neurol [On-line journal], vol (55) pages (937-945). Available online at through

ARF (1996-2002). Standard Medical Workup for Alzheimer's Disease. Alzheimer Research Forum [On-line information]. Available online at through

Family Caregiver Alliance. Fact Sheet: Alzheimer's Disease [On-line information]. Available online at through

Bird, T. (2001 June 22 last update). Alzheimer Overview. GeneReviews [On-line information. Note: It is necessary to register to use GeneReviews, but it is a free site, funded by the NIH]. Available online through

Gottlieb, F. and Lambert, J. G., [Updated by] (2002, January 2, last update). Alzheimer's Disease. MEDLINEplus [On-line information]. Available online at

Miller, M. (1998 February 18). 26 national Alzheimer's Disease Centers Collaborate on Study of the Utility of Genetic Testing for Alzheimer's. National Institutes of Health News Release [On-line press release]. Available online at through

NIH (2000). Progress report on Alzheimer's disease, taking the next steps. NIH Publication No. 00-4859 [On-line report]. Available online at through

UniSci (2002, April 08). New Approaches Seen For Early Alzheimer's Diagnosis. Daily University Science News [On-line Article]. Review of two studies found in Neuropsychology, Vol 16 (2). Available online at through

Eldercare (2002 February 28, last update). Is it Alzheimer's ... or Just Forgetfulness? Sponsored by Nebraska's Area Agencies on Aging [On-line information]. Available online at through

Diagnostic Education, Neurological Disorders, Alzheimer's Disease. Athena Diagnostics [On-line information]. Available online at through

NeuroCast. Neuropathology of Alzheimer's Disease. Athena Diagnostics [On-line information]. Available online at's.shtml through

NeuroCast. Biochemistry of Alzheimer's Disease. Athena Diagnostics [On-line information]. Available online at's.shtml through

Hain, T. (2000 February 13). Alzheimer's Disease. Neurology, Northwestern University Medical School [3rd year neurology medical student curriculum material]. Available online at through

Kleiner-Fisman, G., Updated by (2002 January 2, last update). CSF Collection. MEDLINEplus [On-line information]. Available online at

(Reviewed 2008 December). PSEN1. Genetics Home Reference [On-line information]. Available online at through Accessed August 2009.

Bird, T. (Revised 2009 April 28). Early-Onset Familial Alzheimer Disease. GeneReviews [On-line information]. Available online at∂=alzheimer-early through Accessed August 2009.

Anderson, H et. al. (Updated 2009 June 18). Alzheimer Disease. emedicine [On-line information]. Available online at through Accessed August 2009.

Rogaeva, E. (2009 February 5). The Genetic Profile of Alzheimer's Disease: Updates and Considerations. Medscape Today from Geriatrics & Aging [On-line information]. Available online at through Accessed August 2009.

Mayo Clinic Staff (2008 September 17). Alzheimer's: Is it in your genes? [On-line information]. Available online at through Accessed August 2009.

Ask a Laboratory Scientist

This form enables you to ask specific questions about lab tests. Your questions will be answered by a laboratory scientist as part of a voluntary service provided by one of our partners, American Society for Clinical Laboratory Science.

Thank you for using the Consumer Information Response Service ("the Service") to inquire about the meaning of your lab test results.  The Service is provided free of charge by the American Society for Clinical Laboratory Science, which is one of many laboratory organizations that supports Lab Tests Online.
Please note that information provided through this free Service is not intended to be medical advice and should not be relied on as such. Although the laboratory provides the largest single source of objective, scientific data on patient status, it is only one part of a complex biological picture of health or disease. As professional clinical laboratory scientists, our goal is to assist you in understanding the purpose of laboratory tests and the general meaning of your laboratory results. It is important that you communicate with your physician so that together you can integrate the pertinent information, such as age, ethnicity, health history, signs and symptoms, laboratory and other procedures (radiology, endoscopy, etc.), to determine your health status. The information provided through this Service is not intended to substitute for such consultations with your physician nor specific medical advice to your health condition.
By submitting your question to this Service, you agree to waive, release, and hold harmless the American Society for Clinical Laboratory Science and its affiliates or their past or present officers, directors, employees, agents, and Service volunteers (collectively referred to as "ASCLS") and the American Association  for Clinical Chemistry and its affiliates or their past or present officers, directors, employees, agents, and Service volunteers (collectively referred to as "AACC") from any legal claims, rights, or causes of action you may have in connection with the responses provided to the questions that you submit to the Service.
AACC, ASCLS and its Service volunteers disclaim any liability arising out of your use of this Service or for any adverse outcome from your use of the information provided by this Service for any reason, including but not limited to any misunderstanding or misinterpretation of the information provided through this Service.